Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-24T18:20:10.006Z Has data issue: false hasContentIssue false
  • English
  • Français

162 Add-on Filgrastim During Clozapine Rechallenge Unsuccessful in Treating Benign Ethnic Neutropenia

Published online by Cambridge University Press:  15 June 2018

Molly Britton ,
Palanikumar Gunasekar  and
Vithyalakshmi Selvaraj
Molly Britton
Affiliation:
Psychiatry resident, Department of Psychiatry, Creighton University School of Medicine, Omaha, NE
Palanikumar Gunasekar
Affiliation:
Post doctoral fellow, Department of Clinical Translational Science, Creighton University School of Medicine, Omaha, NE
Vithyalakshmi Selvaraj
Affiliation:
Associate Professor, Department of Psychiatry, Creighton University School of Medicine, Omaha, NE
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Abstract

Clozapine is an atypical antipsychotic approved by the Food and Drug Administration for treatment-resistant schizophrenia and also indicated for the reduction in risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. The most serious side effect of clozapine treatment is agranulocytosis, which is defined as an absolute neutrophil count (ANC) < 0.50 × 109 per L. Benign ethnic neutropenia (BEN) is a condition found in members of African or Middle Eastern descent that is characterized by ANC < 1.50 × 109 per L in the absence of other causes. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that has shown efficacy in reducing the duration of agranulocytosis in some patients who develop clozapine-induced agranulocytosis. It is currently unknown whether filgrastim is beneficial in the treatment of neutropenia due to BEN. We here, for first the time report a case of a patient with BEN who developed agranulocytosis both during the first clozapine trial for schizophrenia and during the rechallenge, despite early stabilization with filgrastim treatment, which highlights the failure of filgrastim in treating BEN.

Funding Acknowledgements

No funding.

Type
Abstracts
Information
CNS Spectrums , Volume 23 , Issue 1 , February 2018 , pp. 98 - 99
Copyright
© Cambridge University Press 2018